KKR Genetic Disorder L.P. → BridgeBio Pharma, Inc. BBIO

Stake: 10.10% Shares: 19,260,971 CUSIP: 10806X102 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) below is incorporated by reference herein.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 14.73

23,366,752 shares short · -0.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $581K

Point72 Asset Mgmt

Post-Filing Returns · since 2025-03-05 on BBIO

+1 day

-7.8%

+5 days

-10.2%

+30 days

-10.3%

+60 days

+9.3%

+90 days

+7.3%

+180 days

+43.0%

Anchor price 34.97 on closest trading day on/after 2025-03-05. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →